Trial · NCT07047547
A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure
NCT07047547, Not applicable, Recruiting, Guangdong Provincial People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure. Trials, record NCT07047547. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07047547
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure
- NCT number
- NCT07047547
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 118 participants, estimated
- Lead sponsor
- Guangdong Provincial People's Hospital
- Conditions
- Hemodialysis Complication, Heart Failure
- Interventions
- Vericiguat
- First posted
- 2025-07-02
- Last updated
- 2025-07-09
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Left ventricular ejection fraction(LVEF) | 12weeks | Change from baseline in left ventricular ejection fraction(LVEF)between baseline and end of study |
| Primary | Left ventricular ejection fraction (LVEF) | 12weeks | Change from baseline in left ventricular ejection fraction (LVEF) between baseline and end of study |
| Secondary | N terminal proB type natriuretic peptide (NT-prpBNP) | 12 weeks | Blood samples will be collected for analysis of concentration of N terminal pro B type natriuretic pel proBNP) every 2 weeks |
| Secondary | Left ventricular end diastolic volume (LVEDV) | 12 weeks | LVEDV is measured as baseline and after 12 weeks follow-up. |
| Secondary | Left atrial volume (LAV) | 12 weeks | LAVis measured as baseline and after 12 weeks follow-up. |
| Secondary | The ratio of mitral early diastolic blood flow peak and mitral annulus velocity (E/E') | 12 weeks | E/E' is measured as baseline and after 12 weeks follow-up. |
| Secondary | Pulmonary Artery Pressure | 12 weeks | Pulmonary Artery Pressure is measured as baseline and after 12 weeks follow-up. |
| Secondary | Concentration of high-sensitivity serum troponin T | 12 weeks | Blood samples will be collected for analysis of concentration of serum troponin every 4 weeks. |
| Secondary | Minnesota Heart Failure Quality of Life Questionnaire (LiHFe) | 12 weeks | Change in health status is assessed using the disease-specific Minnesota Heart Failure Quality of L Questionnaire. |
| Secondary | Systolic and diastolic blood pressure | 12 weeks | Systolic and diastolic blood pressure will be measured every 2 weeks. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07047547
GET https://conductscience.org/api/trials/v1/NCT07047547/registered